GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (NYSE:PFE) » Definitions » Price-to-Owner-Earnings

Pfizer (Pfizer) Price-to-Owner-Earnings

: 433.33 (As of Today)
View and export this data going back to 1951. Start your Free Trial

As of today (2024-04-19), Pfizer's share price is $26.00. Pfizer's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.06. It's Price-to-Owner-Earnings for today is 433.33.


The historical rank and industry rank for Pfizer's Price-to-Owner-Earnings or its related term are showing as below:

PFE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.76   Med: 12.73   Max: 460.47
Current: 406.26

During the past 13 years, the highest Price-to-Owner-Earnings of Pfizer was 460.47. The lowest was 5.76. And the median was 12.73.


PFE's Price-to-Owner-Earnings is ranked worse than
97.15% of 421 companies
in the Drug Manufacturers industry
Industry Median: 27.51 vs PFE: 406.26

As of today (2024-04-19), Pfizer's share price is $26.00. Pfizer's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.36. Therefore, Pfizer's PE Ratio for today is 72.22.

As of today (2024-04-19), Pfizer's share price is $26.00. Pfizer's EPS without NRI for the trailing twelve months (TTM) ended in was $1.83. Therefore, Pfizer's PE Ratio without NRI for today is 14.21.

During the past 13 years, Pfizer's highest PE Ratio without NRI was 18.43. The lowest was 5.94. And the median was 13.19.


Pfizer Price-to-Owner-Earnings Historical Data

The historical data trend for Pfizer's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => 12.47 [6] => 20.23 [7] => 10.13 [8] => 11.83 [9] => 449.84 )
Pfizer Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.47 20.23 10.13 11.83 449.84

Pfizer Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.83 11.88 18.26 46.20 449.84

Competitive Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer Price-to-Owner-Earnings Distribution

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Pfizer's Price-to-Owner-Earnings falls into.



Pfizer Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Pfizer's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=26.00/0.06
=433.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pfizer  (NYSE:PFE) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Pfizer Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Pfizer's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer (Pfizer) Business Description

Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Executives
Scott Gottlieb director MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142
Christoffel Boshoff officer: Executive Vice President 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Jennifer B. Damico officer: SVP & Controller C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Payal Sahni officer: Executive Vice President ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Carapezzi William R Jr officer: Executive Vice President 600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921
Douglas M Lankler officer: Senior Vice President PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Mikael Dolsten officer: Senior Vice President 5 GIRALDA FARMS, MADISON NJ 07940
David M Denton officer: Chief Financial Officer & EVP 1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117
William Pao officer: Executive Vice President C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Michael Mcdermott officer: Executive Vice President C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017
Rady A Johnson officer: Executive Vice President PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Alexander R Mackenzie officer: Executive Vice President C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Sally Susman officer: Senior Vice President 767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153
Angela Hwang officer: Group President 235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017
John D Young officer: Business Unit President C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017